Thermo Fisher Scientific Thermo Fisher Scientific is a biotechnology company engaged in service science. | ET Healthcare ET Healthcare (ETH) is a company that specializes in medical diagnostics and life sciences. | ||||
Founding Date | Founding Date 1956 | Founding Date 1894 | Founding Date 1984 | Founding Date 2008 | Founding Date 2008 |
Type | Type Public | Type Public | Type Public | Type Private | Type Private |
Tags | |||||
Locations | Locations Waltham, US HQ Buenos Aires, AR Buenos Aires, AR Buenos Aires, AR Adelaide Airport, AU Brendale, AU Canberra, AU see more | Locations Abbott Park, US HQ Tiranë, AL Buenos Aires, AR Yerevan, AM Doncaster, AU East Brisbane, AU Macquarie Park, AU see more | Locations Washington, US HQ Mount Waverley, AU Vienna, AT Ghent, BE Sao Paolo, BR Vancouver, CA Shanghai, CN see more | Locations Lille, FR HQ | Locations Palo Alto, US HQ |
Employees | Employees 122,0006% decrease | Employees 114,0001% decrease | Employees 61,00023% decrease | Employees 18 | Employees 274% increase |
Valuation ($) | Valuation ($) 234.6 b | Valuation ($) 196.1 b | Valuation ($) 196.8 b | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $42.9b (FY, 2023) | Revenue (est.) $40.1b (FY, 2023) | Revenue (est.) $23.9b (FY, 2023) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods $25.8b (FY, 2023) | Cost of goods $18b (FY, 2023) | Cost of goods $9.9b (FY, 2023) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $17.1b (FY, 2023) | Gross profit $22.1b (FY, 2023) | Gross profit $14b (FY, 2023) | Gross profit N/A | Gross profit N/A |
Net income | Net income $6b (FY, 2023) | Net income $5.7b (FY, 2023) | Net income $4.2b (FY, 2023) | Net income N/A | Net income N/A |
Operating ⚠ | |||||
Countries | Countries 70 (FY, 2023) | Countries N/A | Countries 50 (FY, 2023) | Countries N/A | Countries N/A |
Remaining Performance Obligations | Remaining Performance Obligations $26.4b (Q1, 2024) | Remaining Performance Obligations N/A | Remaining Performance Obligations $4.5b (Q2, 2024) | Remaining Performance Obligations N/A | Remaining Performance Obligations N/A |
Funding | |||||
Total funding raised | Total funding raised $ 500m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 24.5m |